论文部分内容阅读
我们率先在国内外报道了有关B7基因修饰肝癌细胞对其免疫原性和致瘤性的影响及B7基因修饰的肿瘤细胞疫苗(tumor cell vaccine,TCV)的体内、外抗肿瘤作用.我们的研究发现,在缺乏B7分子的小鼠肝癌细胞Hepal-6与细胞株中导入小鼠B7-1,B7-2基因,能使该肝癌细胞株的免疫原性大大增强,致瘤性完全消失.用丝裂霉素C(MMC)处理转染了B7-1,B7-2基因的小鼠肝癌细胞Hepal-6细胞株,制备成肿瘤细胞疫苗,其抗肿瘤作用明显增强,表现为对论动物的免疫模型起完全的免疫保护作用、对早期模型起部分治疗作用和
We took the lead to report on the effects of B7-modified hepatocellular carcinoma cells on its immunogenicity and tumorigenicity both at home and abroad, and the in vitro and in vivo anti-tumor effects of the B7 genetically modified tumor cell vaccine (TCV). It was found that the introduction of mouse B7-1 and B7-2 genes into mouse hepatocellular carcinoma cell line Hepal-6 lacking B7 molecule can greatly enhance the immunogenicity of the hepatoma cell line and completely eliminate tumorigenicity. The mitomycin C (MMC) treatment of the hepatocellular carcinoma cell line Hepal-6 transfected with the B7-1 and B7-2 genes to prepare a tumor cell vaccine, and its anti-tumor effect was significantly enhanced. The immune model plays a full immune protective role and plays a partial therapeutic role in the early model.